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 Introduction
Breast cancer (BC) to date remains the most 
common cancer in women [1].
The increased incidence is due to wide intro-
duction of mammography screening programs 
and continues to grow with the aging of the popu-
lation, while the prevalence is increasing as a 
consequence of improvements in treatment out-
comes. At the same time, mortality has decreased 
thanks to an efficient screening that enables dis-
ease diagnosis at a very early stage. Moreover, 
chemotherapy and endocrine adjuvant therapy 
have strongly implemented treatment in BC.
Nowadays, BC is often diagnosed at local dis-
ease stage, and, after surgery, based on individu-
al’s risk of relapse, the patients undergo adjuvant 
systemic treatment or/and regional irradiation to 
decrease the risk of recurrence. Some patients, 
however, will eventually develop recurrent or 
metastatic disease.
According to standard practice, the choice of 
treatment strategy includes assays for estrogen 
(ER) and progesterone (PgR) receptor expression 
levels, overexpression of human epidermal 
growth factor receptor 2 (Her-2), or amplification 
status of the correlate oncogene, but also histo-
logical grade and Ki67 to evaluate proliferation 
of tumor cells.
These features result in the identification of 
different clinical subgroups of BC:
• The “luminal” tumors, which express ER and 
PgR receptors and are characterized by endo-
crine responsiveness and further subdivided 
into “luminal A” and “luminal B” according to 
the expression levels of Ki67
• The “Her-2 positive” subgroup, which gets 
clinical benefit from treatment with “trastu-
zumab,” selective monoclonal antibody that 
targets Her-2, used in both early and advanced 
disease settings
• The “triple-negative” subgroup, characterized 
by the absence of the tree receptors, hormonal 
receptors, and Her-2, with, therefore, a lower 
availability of therapeutic options
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On the basis of new molecular diagnostic 
techniques of genomic profiling, today we know 
that to each clinical subgroup of BC corresponds 
a specific molecular subtype with distinct 
genomic signatures, conditioning the biologic 
behavior of tumors [2–4].
Current BC classification and assessment 
remain strongly based on clinicopathological cri-
teria, including patient age, tumor size, lymph 
node invasion, histological type, and grade.
Nevertheless the established clinicopathologi-
cal parameters are not sufficient anymore for risk 
stratification and clinical decision-making, par-
ticularly regarding adjuvant chemotherapy, since 
substantial over- or undertreatment may occur. 
ER, PgR, and Her-2 status, used for many years 
as only validated predictive factors to select 
patients for endocrine treatment and anti-Her-2 
treatments, provide limited information.
Thus, novel molecular markers are under 
investigation to achieve a more precise prognos-
tic and predictive evaluation of disease and a 
more effective “personalized treatment” in BC.
Clinicopathological information should be 
combined with genomic profiling to estimate 
recurrence risk and identify high-risk BC patients 
(prognostic value) and predict optimal treatment 
for each disease subgroup (predictive value).
 Reading the Breast Cancer Genome: 
An Explosion of Biomarker Diversity
The recent introduction of translational analysis 
techniques, mainly next-generation sequencing 
(NGS), has led to an enormous genomic data 
about BC that helped the identification of several 
molecular alterations associated with the distinct 
molecular subtype of BC.
This information has revealed that BC is not a 
single disease but a complex and heterogeneous 
tumor, complicating our understanding toward 
molecular makeup of the tumor.
Over the tumor heterogeneity from different 
individuals (intertumor heterogeneity), even with 
the same clinicopathological features, there is a 
spatial intra-tumor heterogeneity due to subpop-
ulations of tumor cells with different genomic 
alterations coexisting within the same tumor and 
a temporal intra-tumor heterogeneity of different 
cells in the same patients but at different time 
points, for example, between primary tumor and 
its metastasis (Fig. 9.1) [5–7].
This phenomenon represents one of the main 
barriers to precision medicine in breast cancer: 
the information obtained from standard tumor 
tissue sampling cannot be the same for the whole 
tumor and offer a static picture of disease. The 
constant molecular change of tumor cell popula-
tion, spatial and temporal, requires a noninvasive 
approach, for real-time picture of disease. Liquid 
biopsy is a useful tool to follow the continuously 
evolving genomic landscape of breast cancer [8–
10] (Fig. 9.2).
 Circulating Tumor DNA (ctDNA)
Several studies have shown that ctDNA can be 
used in clinical practice for evaluation and 
decision- making in the diagnosis, treatment, and 
follow-up of breast cancer patients [11]. Indeed, 
it has been demonstrated that high levels of 
ctDNA correlate with tumor size, lymph node 
involvement, histopathological grade, and clini-
cal staging [11, 12]. ctDNA is easier to detect in 
patients with metastatic breast cancer compared 
to patients that have a localized disease and con-
centrations of ctDNA increased with advanced 
stage of cancer [13].
Different researchers have focused on muta-
tional analysis of genes directly involved in 
breast cancer both in patients with an advanced- 
stage disease and in patients with localized dis-
ease. Some studies have quantified the presence 
of tumor-specific alterations in ctDNA. In the 
screening and diagnosis of breast cancer, patient- 
specific mutations are not known before. 
Therefore, these studies have focused on cancer- 
associated alterations that are common in all 
types of breast cancers. Chimonidou et al. found 
CST6 promoter methylation in plasma ctDNA in 
13–40% of breast cancer patients but none in 
healthy patients [14]. Accordingly, Dulaimi et al. 
found hypermethylation of promoters RASSF1A, 
APS, and DAP kinase in the serum of 70% breast 
cancer patients and none in serum from healthy 
subjects [15]. Oshiro et al. developed a digital 
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PCR assay to evaluate three hotspot PIK3CA 
mutations, which is one of the main gene involved 
in breast cancer tumorigenesis [3]. Again by 
comparing healthy women with stage I–III breast 
cancer patients, it was shown that PIK3CA muta-
tions in ctDNA were only detectable in the latter 
group [16] with a frequency of 23% (Fig. 9.3). 
Interestingly, Board et al. detected PIK3CA 
mutations in ctDNA in 80% of patients with met-
astatic cancer, demonstrating that advanced 
patients have more circulating DNA [17]. In 
another study, it showed that ctDNA was detect-
able in 86% of patients with advanced breast can-
cer but only 50% of patients with localized 
disease and at early stage [18].
Some studies have used baseline ctDNA lev-
els to predict patients’ prognosis, but results 
obtained are contradictory. Iqbal et al. performed 
a comprehensive analysis of circulating cell-free 
DNA in serum by the evaluation of DNA integ-
rity index. To this end, qPCR analysis of Alu 
sequencing using fragments of 115 bp and 
247 bp was performed in 148 BC patients at 
baseline, 47 patients postoperative, and 51 
healthy controls. They showed that DNA integ-
rity was significantly higher in stage IV than ear-
lier stages, and it decreases after surgery. 
Moreover, DNA integrity was able to stratify 
patients in two groups, relapsed and disease-free 














Fig. 9.1 Tumor 
heterogeneity in breast 
cancer: (a) intertumor 
heterogeneity, (b) spatial 
intra-tumor 
heterogeneity, and (c) 
temporal intra-tumor 
heterogeneity
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patients. Baseline serum levels of cell-free DNA 
and its integrity were found thus to be potential 
prognostic biomarkers in patients with primary 
breast cancer [19]. On the contrary, it was shown 
that OS is not associated with ctDNA levels at 
baseline [20]. Therefore, in contrast with CTCs 
that have been suggested to be strong prognostic 
factors, the impact of baseline ctDNA levels is 
still doubtful [21].
ctDNA may also be used to monitor treatment 
efficacy. Recent studies in breast cancer patients 
have found a decrease in ctDNA concentrations 
after surgery and chemotherapy. This prompted 
further studies into the use of ctDNA as a marker 
of treatment response [22]. Dawson et al. have 
compared ctDNA and CTCs for the monitoring of 
response to therapy in metastatic breast cancer 
patients. In this study, somatic mutations and 
Circulating 











Fig. 9.2 Standard biopsy and liquid biopsy in breast cancer: the differences for a “picture” of disease
313 BC pts
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representation of the 
Oshiro study design
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structural variants were first analyzed in tumor tis-
sue and then confirmed in plasma samples using 
both a microfluidic digital PCR assay and sequenc-
ing. ctDNA was detected in 29 of 30 women in 
115 of 141 plasma samples collected during 
2 years’ time. Fluctuations in ctDNA correlate 
with treatment responses as also confirmed by 
imaging analysis. For 19 women who had progres-
sive disease on CT imaging, 17 had growing levels 
of ctDNA, whereas only 7 had also CTC increase. 
In 10 of the 19 patients with progression, ctDNA 
increased an average of 5 months before the estab-
lishment of progressive disease on imaging. 
Increasing levels of both ctDNA and CTCs were 
associated with inferior OS. This group have found 
that ctDNA have a superior sensitivity and 
improved correlation with changes in tumor bur-
den, promoting a better measure of treatment 
effectiveness for metastatic patients [23].
ctDNA can also be used to investigate tumor 
heterogeneity and clonal evolution. It is known in 
the literature that the metastatic cancer has differ-
ent characteristics than the primary tumor [24]. 
Primary tumor biopsies cannot follow the evolu-
tionary changes between metastatic lesions and 
primary tumor [25]. Despite these data, the cur-
rent treatment decisions are often based on the 
molecular profile of the primary tumor without 
taking into consideration the heterogeneity of 
metastatic cancer. Moreover, many patients 
refuse a second tissue biopsy because the tech-
nique is very invasive and painful. Given that the 
ctDNA is released from all tumor components, it 
may provide a more complete molecular profile 
of changing subclone populations and better 
guide therapy [26]. De Mattos-Arruda et al. 
examined primitive tumor DNA, liver metastasis 
DNA, and ctDNA collected from plasma at dif-
ferent time points in one patient with ER+/HER2 
invasive ductal lobular carcinoma with liver 
metastasis. They identified 16 mutations in the 
liver metastasis, and only 9 were also detectable 
in the primary tumor. Thus, ctDNA may provide 
a more complete picture of the mutational land-
scape of metastatic disease.
Based on the previously mentioned studies, it 
can be stated that the ctDNA could be become a 
valid biomarker with applications from diagnosis 
to prognosis but also for the monitoring of tumor 
evolution and therapy response, but numerous 
studies are still needed to go all in one direction.
 Minimal Residual Disease (MRD)
Nowadays, one of the main attempts in breast 
cancer management is testing the feasibility of 
liquid biopsies to evaluate the minimal residual 
disease (MRD). The term MRD can be defined as 
the lowest levels of residual disease after a cura-
tive approach either surgical or pharmacological. 
In fact, evidence of MRD after first-line treat-
ment may be clinically useful to decide whether 
an adjuvant treatment is requested in order to 
avoid any possibility of disease recurrence [27].
In the perspective of a painless and noninva-
sive monitoring of the disease over time, liquid 
biopsies can be easily used as a feasible tool to 
monitor MRD also in breast cancer. In particular, 
MRD represents a higher challenging clinical 
condition in early-stage tumors (nonmetastatic), 
while the spread of circulating biomarkers 
(ctDNA, CTCs) from primary tumor is still not 
massive. To date, big efforts are still needed to 
identify which patients, among those who under-
went to curative surgery, are completely disease- 
free from those who still present hidden residual 
disease that causes relapse. Moreover, a proper 
evaluation of MRD could spare disease-free 
patients from receiving useless but still aggres-
sive adjuvant chemotherapy [28]. Therefore, the 
detection of ctDNA prior and after surgery and/or 
radiotherapeutic intervention would be funda-
mental in predicting residual disease [29]. In 
2014, Beaver and its group attempted for the first 
time to highlight the use of liquid biopsy for 
stratifying patients on the basis of the risk of 
recurrence in a relatively small cohort of 30 
early-stage breast cancer patients. Indeed, by 
using droplet digital PCR (ddPCR), PIK3CA 
exon 9 and 20 mutations have been assessed in 
primary breast tumors and paired pre- and post-
surgery plasma samples of ER+/PR+ early-stage 
breast cancer patients (Fig. 9.4). The presurgery 
tissue samples have been firstly analyzed by 
Sanger sequencing for PIK3CA mutations and 
then confirmed by ddPCR. The digital approach 
showed five more patients (15/30) positive for 
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PIK3CA mutation with respect to the previous 
approach. Circulating plasma DNA has been then 
extracted from pre- and postsurgery blood sam-
ples. PIK3CA mutational analysis through 
ddPCR on presurgery plasma samples showed 
that of the 15 PIK3CA mutations previously 
detected in FFPE samples, 14 mutations have 
been also found in the paired plasma samples 
with high sensitivity (93.3%) and specificity 
(100%). Postsurgery plasma samples have been 
collected, at times ranging from 15 to 72 days 
after surgery, from 10/15 patients with PIK3CA 
mutations detected in plasma DNA before sur-
gery. Indeed, five patients had detectable ctDNA 
demonstrating a still-residual disease despite any 
clinical or radiological evidence of disease [30]. 
More recently, Garcia-Murillas et al. have traced 
PIK3CA mutation in plasma samples to predict 
relapse in early-stage tumors. In this prospective 
study, the ddPCR analysis of 55 plasma samples 
of early breast cancer patients under neoadjuvant 
chemotherapy was able to anticipate almost 
8 months the clinical evidence of metastatic 
relapse [31]. In 2016, the group of Riva et al. 
focused on the feasibility of liquid biopsy for the 
detection of MRD in a cohort of nonmetastatic 
TBNC patients during neoadjuvant chemother-
apy (NCT). Plasma samples were collected at 
four different time points: before NCT, after 
one cycle, presurgery, and postsurgery for 36/40 
TNBC patients. The analysis of ctDNA has been 
performed through ddPCR, analyzing TP53 
mutations, one of the most common genetic alter-
ations in TNBC. ddPCR analysis showed that 
before NCT, ctDNA was detected in 27/36 
patients, and its levels were significantly corre-
lated with tumor size, tumor stage, as well as 
mitotic index. After the first NCT cycle, a remark-
able decrease of ctDNA levels has been showed 
for all patients except for one who instead showed 
increased ctDNA levels. Interestingly, this patient 
experienced disease progression during chemo-
therapy. Furthermore, no patients showed detect-
able ctDNA after surgery [32]. Therefore, liquid 
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 PI3Ks: a family of lipid kinases grouped in 3 classes (PIP2 to PIP3)
 Class IA PI3Ks: heterodimeric proteins
 PIK3CA (encoded p110a): proto-oncogene, chromosome 3 (3q26.3), 20 encoding exons
 PIK3CA mutations in BC: 35-40%
 Hot-spot of mutation: Exon 9 (60-65%) and Exon 20 (20-25%)
 Mutations in exon 9 PIK3CA co-existed with RAS and BRAF mutation
Fig. 9.4 Molecular and biochemical characteristics of PIK3CA domains
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biopsy seems to represent a valuable option in the 
management and monitoring of breast cancer 
patients. In particular, in minimal residual dis-
ease, the detectability of circulating biomarkers 
in early-stage disease would open thus the possi-
bility to enroll these patients in specific surveil-
lance programs and consequently get future 
benefits through longer-term follow-up.
 Circulating Tumor Cells (CTCs)
The hematogenous spread of single tumor cells 
from the primary tumor was first demonstrated in 
the nineteenth century. In the beginning, the aim 
was to investigate disseminated tumor cells 
(DTCs) in the bone marrow. Indeed, in 2005, it 
was first published a multicenter pooled meta- 
analysis that assessed the prognostic significance 
of DTCs in the bone marrow at the time of diag-
nosis. In particular, the study included 4703 
patients diagnosed with stage I, II, and III breast 
cancer and followed over a 10-year follow-up 
period. This study highlighted for the first time 
that patients with bone marrow micrometastasis 
have larger tumors and tumors with a higher his-
tological grade. Moreover, those patients have 
lymph node metastasis and hormone-receptor 
negative tumors. The presence of micrometasta-
sis was a significant prognostic factor with 
respect to poor overall survival and breast cancer- 
specific survival (univariate mortality ratios, 2.15 
and 2.44, respectively; p < 0.001 for both out-
comes) and poor disease-free survival and 
distant- disease-free survival during the 10-year 
observation period (incidence rate ratios, 2.13 
and 2.33, respectively; p < 0.001 for both out-
comes) (reference).
Nowadays, big efforts are still needed to 
improve the molecular characterization of a 
highly heterogeneous tumor. Indeed, studying 
CTCs would be helpful to improve clinical out-
come in particular in triple-negative breast cancer 
(TNBC). Recently, Angelaki et al. studied CTC 
phenotype in a cohort including early-stage and 
metastatic TNBC and hormone-positive breast 
cancers before and after adjuvant chemotherapy. 
Expression of ER, PR, CK, HER2, and EGFR on 
CTCs has been assessed through immunochemis-
try. In early-stage TNBC, before any adjuvant 
chemotherapy, the predominant CTC phenotypes 
were ER+ (24.4%), PR+ (24.4%), CK+/HER2+ 
(20%), and CK+/EGFR+ (40%). Moreover, in 
early-stage TNBC, a high risk of relapse is cor-
related with the CK+/HR- phenotype, and, in 
particular, the CK+/PR- phenotype is often 
accompanied by decreased DFI (p = 0.04) and 
OS (p = 0.032), demonstrating that these cells 
may have an aggressive metastatic potential. This 
study also focused on characterizing CTC sub-
population after adjuvant treatment. Indeed, 
immunochemistry showed a decreased isolation 
of HER2-positive CTCs in comparison to ER/PR 
CTCs. In fact, we can speculate that chemother-
apy does not have the same efficacy against all 
CTC subpopulations. Otherwise, in metastatic 
cancer, the incidence of CK+/HER2+ CTCs was 
higher than the early-stage counterpart. Indeed, 
this finding can predict a more aggressive behav-
ior during disease evolution [33]. The prognostic 
value of CTC count with respect to the most 
known unfavorable prognostic factors as 
progression- free survival (PFS) and overall survi-
vor (OS) has been deeply evaluated in breast can-
cer. In the study from Bidard et al., CTC count has 
been evaluated through the CellSearch method 
before starting a new treatment and after 3–5 and 
6–8 weeks after the treatment in a cohort of 2400 
patients recruited among 19 different centers. In 
fact, they demonstrated that a number of five 
CTCs per 7.5 mL or higher are often associated 
with decreased PFS and OS if compared with 
patients with a number of CTCs less than 5 per 
7.5 mL. Moreover, increased CTC number both at 
time 3–5 and 6–8 weeks after the new treatment is 
significantly correlated with shortened PFS and 
OS and overall to poorer prognosis [34].
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